within Pharmacolibrary.Drugs.ATC.S;

model S01LA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0027 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.0024,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Abicipar pegol is a designed ankyrin repeat protein (DARPin) that acts as a vascular endothelial growth factor A (VEGF-A) inhibitor. It was developed for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema by intravitreal injection. The drug showed prolonged intraocular half-life, allowing reduced injection frequency compared with existing anti-VEGF therapies. Despite positive efficacy results, abicipar pegol was not approved for clinical use due to safety concerns related to intraocular inflammation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adults with neovascular AMD following single-dose intravitreal administration.</p><h4>References</h4><ol><li><p>Ferro Desideri, L, et al., &amp; Nicolò, M (2020). Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration. <i>Expert opinion on investigational drugs</i> 29(7) 651–658. DOI:<a href=&quot;https://doi.org/10.1080/13543784.2020.1772754&quot;>10.1080/13543784.2020.1772754</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32479126/&quot;>https://pubmed.ncbi.nlm.nih.gov/32479126</a></p></li><li><p>Edington, M, et al., &amp; Chong, NV (2017). Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. <i>Expert opinion on drug metabolism &amp; toxicology</i> 13(12) 1217–1224. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2017.1404987&quot;>10.1080/17425255.2017.1404987</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29134820/&quot;>https://pubmed.ncbi.nlm.nih.gov/29134820</a></p></li><li><p>Luu, KT, et al., &amp; Attar, M (2020). A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition. <i>The Journal of pharmacology and experimental therapeutics</i> 373(2) 184–192. DOI:<a href=&quot;https://doi.org/10.1124/jpet.119.263178&quot;>10.1124/jpet.119.263178</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32098861/&quot;>https://pubmed.ncbi.nlm.nih.gov/32098861</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01LA07;
